Loading…
Back To Schedule
Tuesday, June 20 • 2:00pm - 3:15pm
#258: Patient-Reported Outcomes (PROs): Hot Topics - Part 1 of 2

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Component Type: Session
Level: Advanced
CE: ACPE 1.25 Knowledge UAN: 0286-0000-17-556-L04-P; CME 1.25; IACET 1.25; RN 1.25

Patient-reported outcomes (PROs)are not new. The FDA released a final guidance on this topic in 2009, and there have been many presentations and discussions on the evidence and measurement principles used to guide development of fit-for-purpose PRO assessments. This session will move the conversation from basic PRO development to discuss the latest hot topics regarding PROs in drug development. Hot topics might include (but are not limited to): FDA's flexibility in implementing principles in the guidance; methods to evaluate meaningful change on PRO assessments; strategies for incorporating PRO endpoints into multiplicity-adjusted endpoint hierarchy with traditional endpoints; novel methods to validate new PRO tools).

Learning Objectives

Summarize practical insights and methods that can be used to facilitate the development and use of PROs in clinical trials.

Chair

Selena Daniels, PharmD, MS

Speaker

Capturing the Patient's Voice in Evaluating Safety and Tolerability: Industry Perspective
Arnold Degboe, MD, PhD, MBA

Capturing the Patients’ Voice in the Evaluation of Safety and Tolerability: FDA Perspective
Paul Kluetz, MD

Capturing the Patients’ Voice in the Evaluation of Safety and Tolerability: FDA Perspective
Ann Marie Trentacosti, MD


Speakers
avatar for Selena Daniels

Selena Daniels

Team Leader, Division of Clinical Outcome Assessment, ODES, CDER, FDA, United States
Dr. Selena Daniels serves as a Team Leader in the Division of Clinical Outcome Assessment at the Food and Drug Administration (FDA). She leads a team of expert analysts who provide consultation and advice on clinical outcome assessment (COA) endpoint development and validation, including... Read More →
avatar for Arnold Degboe

Arnold Degboe

Director, Patient Science-Oncology, Patient Centricity, Global Medical Affairs, AstraZeneca
Arnold is a physician by training and a health economics & outcomes researcher with over 16 years of combined experience in clinical practice, outcomes research and pharma. He holds a medical degree from Ghana, and a dual-titled Ph.D. in Health Policy & Demography from Penn State... Read More →
avatar for Paul Kluetz

Paul Kluetz

Deputy Director, Oncology Center of Excellence, OC, FDA, United States
Paul Kluetz is a medical oncologist and the Associate Director of Patient Outcomes in the Oncology Center of Excellence at the U.S. FDA. His interests include defining clinical benefit in oncology trials, the use of expedited programs such as accelerated approval, and opportunities... Read More →
avatar for Ann Marie Trentacosti

Ann Marie Trentacosti

Medical Officer, Labeling Development Team, OND, CDER, FDA
Dr. Ann Marie Trentacosti is the Medical Lead for the Labeling Development Team (LDT) in the Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA). LDT ensures that the prescribing information is a useful communication tool... Read More →

Tuesday June 20, 2017 2:00pm - 3:15pm CDT
S404d McCormick Place 2301 South Martin Luther King Jr. Drive, Gate 4 Chicago, IL 60616
  09: TranslSci-Preclin-Clin-ProdDev, Session